BNTX: financial statements from SEC — TradeAlmanac

BNTX

BioNTech SE: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	2.87bn	2.75bn	3.82bn	17.31bn
Cost of revenue	642m	541m	600m	3.00bn
Research and development	2.10bn	2.25bn	1.78bn	1.54bn
Selling, general and administrative	514m	531m	495m	482m
Operating income	−1.40bn	−1.31bn	690m	12.64bn
Pre-tax income	−1.05bn	−678m	1.19bn	12.95bn
Income tax	85m	−12m	256m	3.52bn
Net income	−1.14bn	−665m	930m	9.43bn
Earnings per share	−4.70	−2.77	3.87	38.78
Earnings per share, diluted	−4.70	−2.77	3.83	37.77

Balance sheet

Metric	Aug 18, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash and equivalents	—	7.68bn	9.76bn	11.66bn	13.88bn	1.69bn
Receivables	—	924m	1.46bn	2.16bn	—

Cash flow

Metric	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Operating cash flow	456m	208m	5.37bn	13.58bn
Depreciation and amortisation	383m	298m	183m	123m
Share-based compensation	106m	101m	51m	109m
Capital expenditure

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)